BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, February 17, 2026
Home » Authors » James Etheridge

Articles by James Etheridge

Innate Pharma, Novo Nordisk Refocus Efforts on Inflammation

Feb. 6, 2008
By James Etheridge

Endotis Pharma Raises €25M to Move Small Glyco-Drugs

Jan. 30, 2008
By James Etheridge

Endotis Pharma Raises €25M to Move Small Glyco-Drugs

Jan. 30, 2008
By James Etheridge
No Abstract
Read More

Novexel Receives €75M Up Front for Beta Lactamase Inhibitor

Jan. 23, 2008
By James Etheridge

Novexel Receives €75M Up Front for Beta Lactamase Inhibitor

Jan. 23, 2008
By James Etheridge
Novexel SA and Forest Laboratories Holdings Ltd., a wholly owned subsidiary of Forest Laboratories Inc. signed an agreement allowing the U.S. company to develop, manufacture and commercialize Novexel's novel intravenous beta lactamase inhibitor, NXL104, in combination with Forest's ceftaroline. (BioWorld International)
Read More

Novexel Receives €75M Up Front for Beta Lactamase Inhibitor

Jan. 23, 2008
By James Etheridge
No Abstract BioWorld Today CorrespondentPARIS - Novexel SA and Forest Laboratories Holdings Ltd., a wholly owned subsidiary of Forest Laboratories Inc. signed an agreement allowing the U.S. company to develop, manufacture and commercialize Novexel's novel intravenous beta lactamase inhibitor, NXL104, in combination with Forest's ceftaroline.
Read More

Novexel Receives €75M Up Front for Beta Lactamase Inhibitor

Jan. 23, 2008
By James Etheridge
Novexel SA and Forest Laboratories Holdings Ltd., a wholly owned subsidiary of Forest Laboratories Inc. signed an agreement allowing the U.S. company to develop, manufacture and commercialize Novexel's novel intravenous beta lactamase inhibitor, NXL104, in combination with Forest's ceftaroline. (BioWorld International) 
Read More

France Suspends Cultivation of Monsanto's GM Corn

Jan. 16, 2008
By James Etheridge
PARIS - France has suspended the cultivation of genetically modified corn, which means Monsanto's MON 810 corn, the only GM corn containing a pesticide that was authorized for commercial cultivation in the country. (BioWorld International)
Read More

Genfit, Pierre Fabre Renew Metabolic Disorders Pact

Jan. 16, 2008
By James Etheridge

Genfit, Pierre Fabre Renew Metabolic Disorders Pact

Jan. 16, 2008
By James Etheridge
Previous 1 2 … 6 7 8 9 10 11 12 13 14 … 90 91 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing